Ibrutinib in B lymphoid malignancies (Q38545545)

4 September 2017

1 reference

title

Ibrutinib in B lymphoid malignancies (English)

1 reference

4 September 2017

1 reference

Mitchell R Smith

1

1 reference

PubMed ID

26165513

4 September 2017

language of work or name

English

0 references

publication date

13 July 2015

1 reference

Expert Opinion on Pharmacotherapy

4 September 2017

1 reference

4 September 2017

16

1 reference

4 September 2017

12

1 reference

4 September 2017

1879-1887

1 reference

4 September 2017

Cancer statistics, 2015

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1067302

Waldenstrom macroglobulinemia: prognosis and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1067302

Chronic lymphocytic leukemia: 2015 Update on diagnosis, risk stratification, and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1067302

U.S. Food and Drug Administration approval: ofatumumab for the treatment of patients with chronic lymphocytic leukemia refractory to fludarabine and alemtuzumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1067302

U.S. Food and drug administration approval: obinutuzumab in combination with chlorambucil for the treatment of previously untreated chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1067302

U.S. Food and Drug Administration approval summary: brentuximab vedotin for the treatment of relapsed Hodgkin lymphoma or relapsed systemic anaplastic large-cell lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1067302

Bortezomib for the treatment of mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1067302

An evidence-based review of ixazomib citrate and its potential in the treatment of newly diagnosed multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1067302

Romidepsin for the treatment of relapsed/refractory peripheral T-cell lymphoma: pivotal study update demonstrates durable responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1067302

A Phase II trial of Belinostat (PXD101) in patients with relapsed or refractory peripheral or cutaneous T-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1067302

Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1067302

MCL-1 and BCL-xL-dependent resistance to the BCL-2 inhibitor ABT-199 can be overcome by preventing PI3K/AKT/mTOR activation in lymphoid malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1067302

ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1067302

An open-label phase 2 trial of entospletinib (GS-9973), a selective spleen tyrosine kinase inhibitor, in chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1067302

FDA approval: idelalisib monotherapy for the treatment of patients with follicular lymphoma and small lymphocytic lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1067302

Deficient expression of a B cell cytoplasmic tyrosine kinase in human X-linked agammaglobulinemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1067302

The gene involved in X-linked agammaglobulinaemia is a member of the src family of protein-tyrosine kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1067302

The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1067302

Population pharmacokinetic model of ibrutinib, a Bruton tyrosine kinase inhibitor, in patients with B cell malignancies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1067302

Egress of CD19(+)CD5(+) cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1067302

Ibrutinib increases the risk of atrial fibrillation, potentially through inhibition of cardiac PI3K-Akt signaling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1067302

Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1067302

Ibrutinib inhibits collagen-mediated but not ADP-mediated platelet aggregation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1067302

Ibrutinib treatment affects collagen and von Willebrand factor-dependent platelet functions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1067302

Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1067302

Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1067302

Ibrutinib-induced lymphocytosis in patients with chronic lymphocytic leukemia: correlative analyses from a phase II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1067302

Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1067302

Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1067302

Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1067302

Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1067302

Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1067302

Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1067302

MYD88 L265P somatic mutation in Waldenström's macroglobulinemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1067302

A mutation in MYD88 (L265P) supports the survival of lymphoplasmacytic cells by activation of Bruton tyrosine kinase in Waldenström macroglobulinemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1067302

Ibrutinib in previously treated Waldenström's macroglobulinemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1067302

The WHIM-like CXCR4(S338X) somatic mutation activates AKT and ERK, and promotes resistance to ibrutinib and other agents used in the treatment of Waldenstrom's Macroglobulinemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1067302

Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1067302

Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1067302

Cell-cycle reprogramming for PI3K inhibition overrides a relapse-specific C481S BTK mutation revealed by longitudinal functional genomics in mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1067302

Patients with mantle cell lymphoma failing ibrutinib are unlikely to respond to salvage chemotherapy and have poor outcomes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1067302

Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1067302

Ibrutinib antagonizes rituximab-dependent NK cell-mediated cytotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1067302

Ibrutinib interferes with the cell-mediated anti-tumor activities of therapeutic CD20 antibodies: implications for combination therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1067302

Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1067302

Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1067302

The Bruton tyrosine kinase inhibitor ibrutinib with chemoimmunotherapy in patients with chronic lymphocytic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1067302

Phase 2 study of VcR-CVAD with maintenance rituximab for untreated mantle cell lymphoma: an Eastern Cooperative Oncology Group study (E1405).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1067302

Treatment of older patients with mantle-cell lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1067302

Combination of ibrutinib with ABT-199: synergistic effects on proliferation inhibition and apoptosis in mantle cell lymphoma cells through perturbation of BTK, AKT and BCL2 pathways.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1067302

10.1517/14656566.2015.1067302

21 January 2018

Identifiers

DOI

1 reference

4 September 2017

1 reference

PubMed ID

26165513